@su2cscience.bsky.social
Dr. Julian Adams, President and CEO of @su2c.bsky.social, is at the @milkeninstitute.org today discussing innovations in #EarlyDetection and equitable cancer care. Panelists include @boehmjesse.bsky.social from @break-cancer.bsky.social, Ian Foulkes from @cancerresearchuk.org, and Maddie Musselman
November 6, 2025 at 10:20 PM
Dr. Julian Adams, President and CEO of @su2c.bsky.social, is at the @milkeninstitute.org today discussing innovations in #EarlyDetection and equitable cancer care. Panelists include @boehmjesse.bsky.social from @break-cancer.bsky.social, Ian Foulkes from @cancerresearchuk.org, and Maddie Musselman
Last week, Dr. Julian Adams, President and CEO of @su2c.bsky.social, spoke at the #LongwoodHealthcareLeaders #BostonCEO 2025. The event covered a wide range of topics, including health equity and patient access to care. It was attended by top leaders in healthcare and select Nobel Laureates.
November 6, 2025 at 3:20 PM
Last week, Dr. Julian Adams, President and CEO of @su2c.bsky.social, spoke at the #LongwoodHealthcareLeaders #BostonCEO 2025. The event covered a wide range of topics, including health equity and patient access to care. It was attended by top leaders in healthcare and select Nobel Laureates.
Will Freed-Pastor from @danafarber.bsky.social gave a phenomenal presentation on cryptic #antigens and their potential as targets for TCR-based therapies at the @theaacr.bsky.social Special Conference in #PancreaticCancer Research.
October 8, 2025 at 7:42 PM
Will Freed-Pastor from @danafarber.bsky.social gave a phenomenal presentation on cryptic #antigens and their potential as targets for TCR-based therapies at the @theaacr.bsky.social Special Conference in #PancreaticCancer Research.
The 18th @theaacr.bsky.social Conference on the Science of #HealthDisparities took place in Baltimore from September 18-21. A special session held on Saturday featured a panel discussion, grantees, advocates, and other members of the @su2c.bsky.social community. Thanks to all in attendance!
September 22, 2025 at 3:38 PM
The 18th @theaacr.bsky.social Conference on the Science of #HealthDisparities took place in Baltimore from September 18-21. A special session held on Saturday featured a panel discussion, grantees, advocates, and other members of the @su2c.bsky.social community. Thanks to all in attendance!
Michael Goggins, Maria Irene Canto, and a team of @su2c.bsky.social and @lustgarten.org funded researchers at @hopkinsmedicine.bsky.social have found a link between dilation of the #pancreatic duct and the development of #pancreaticcancer in high-risk individuals. www.ghadvances.org/article/S277...
Mild dilatation of the main pancreatic duct is a risk factor for progression to pancreatic cancer in high-risk individuals
Mild dilatation of the main pancreatic duct (MPD) can be an early indicator of an
obstructing mass, but its clinical significance in asymptomatic high-risk individuals
(HRI) undergoing surveillance ha...
www.ghadvances.org
September 16, 2025 at 1:52 PM
Michael Goggins, Maria Irene Canto, and a team of @su2c.bsky.social and @lustgarten.org funded researchers at @hopkinsmedicine.bsky.social have found a link between dilation of the #pancreatic duct and the development of #pancreaticcancer in high-risk individuals. www.ghadvances.org/article/S277...
The Data for Children's and Young People's Cancer Programme Award is a new partnership between @su2c.bsky.social and @cancerresearchuk.org to support data-driven solutions to common challenges in this space.
More information: cruk.ink/4njVxWU
Informational webinar: cruk.ink/4gdAcw9
More information: cruk.ink/4njVxWU
Informational webinar: cruk.ink/4gdAcw9
September 12, 2025 at 4:14 PM
The Data for Children's and Young People's Cancer Programme Award is a new partnership between @su2c.bsky.social and @cancerresearchuk.org to support data-driven solutions to common challenges in this space.
More information: cruk.ink/4njVxWU
Informational webinar: cruk.ink/4gdAcw9
More information: cruk.ink/4njVxWU
Informational webinar: cruk.ink/4gdAcw9
The @su2c.bsky.social Catalyst®-@genentech.bsky.social Team lpublished the results of Arm C of the NeoACTIVATE trial in the European Journal of Cancer showing that neoadjuvant atezolizumab/tiragolumab is a promising treatment regimen in stage III melanoma www.ejcancer.com/article/S095...
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma
Neoadjuvant ± adjuvant immunotherapy improves event-free survival (EFS) versus adjuvant
immunotherapy alone for high-risk resectable Stage III melanoma. However, the optimal
regimen balancing efficacy...
www.ejcancer.com
August 12, 2025 at 12:24 PM
The @su2c.bsky.social Catalyst®-@genentech.bsky.social Team lpublished the results of Arm C of the NeoACTIVATE trial in the European Journal of Cancer showing that neoadjuvant atezolizumab/tiragolumab is a promising treatment regimen in stage III melanoma www.ejcancer.com/article/S095...
A study in NatureComms uses #ML and a clinicogenomic dataset generated by the @su2c.bsky.social -@ @acscan.bsky.social Lung Cancer Dream Team to improve immune checkpoint monotherapy or combination #immunotherapy-#chemotherapy for patients with #NSCLC. www.nature.com/articles/s41...
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC - Nature Communications
The approval of first line immune checkpoint blockade (ICB) has improved outcomes for patients with metastatic non-small cell lung cancer (mNSCLC), however, whether patients would benefit more from IC...
www.nature.com
July 29, 2025 at 8:23 PM
A study in NatureComms uses #ML and a clinicogenomic dataset generated by the @su2c.bsky.social -@ @acscan.bsky.social Lung Cancer Dream Team to improve immune checkpoint monotherapy or combination #immunotherapy-#chemotherapy for patients with #NSCLC. www.nature.com/articles/s41...
Request for Applications! The @su2c.bsky.social - @CRUK Prevention, Early Stage Detection, and Interception of Recurrence Challenge is now open! For more information, click the link below or search Stand Up To Cancer in Proposal Central under Grant Opportunities. standuptocancer.org/science/gran...
July 25, 2025 at 5:30 PM
Request for Applications! The @su2c.bsky.social - @CRUK Prevention, Early Stage Detection, and Interception of Recurrence Challenge is now open! For more information, click the link below or search Stand Up To Cancer in Proposal Central under Grant Opportunities. standuptocancer.org/science/gran...
According to a paper published in @cp-cancercell.bsky.social by the @su2c.bsky.social Colorectal Cancer Dream, they have been able to use mutagenic agents to engineer an MMRd genotype in immunoresistant cells to generate an immunogenic phenotype
www.cell.com/cancer-cell/...
www.cell.com/cancer-cell/...
Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer
Rousseau et al. show that tailored mutagenic chemical treatment induces a mismatch
repair deficient genotype by epigenetic Msh2 silencing leading to potent immune response
in immunoresistant tumor mod...
www.cell.com
July 21, 2025 at 6:02 PM
According to a paper published in @cp-cancercell.bsky.social by the @su2c.bsky.social Colorectal Cancer Dream, they have been able to use mutagenic agents to engineer an MMRd genotype in immunoresistant cells to generate an immunogenic phenotype
www.cell.com/cancer-cell/...
www.cell.com/cancer-cell/...
The GBM chatbot is going live on the @su2c.bsky.social website on 7/16. This AI companion was developed by Jason Binder after his wife was diagnosed with glioblastoma to help patients and family members to understand glioblastoma, explore options, and feel less alone on this journey. #GBMDay
July 16, 2025 at 3:28 PM
The GBM chatbot is going live on the @su2c.bsky.social website on 7/16. This AI companion was developed by Jason Binder after his wife was diagnosed with glioblastoma to help patients and family members to understand glioblastoma, explore options, and feel less alone on this journey. #GBMDay
@su2c.bsky.social Convergence 3.1416 Research Team member Raul Rabadan published a review in @CR_AACR examining examples of noncoding mutations in cancer and comparing key AI models developed over the last decade for uncovering cancer-associated noncoding mutations. aacrjournals.org/cancerres/ar...
Illuminating the Noncoding Genome in Cancer Using Artificial Intelligence
Abstract. Understanding the vast noncoding cancer genome requires cutting-edge, high-resolution, and accessible strategies. Artificial intelligence is revolutionizing cancer research, enabling advance...
aacrjournals.org
July 15, 2025 at 6:47 PM
@su2c.bsky.social Convergence 3.1416 Research Team member Raul Rabadan published a review in @CR_AACR examining examples of noncoding mutations in cancer and comparing key AI models developed over the last decade for uncovering cancer-associated noncoding mutations. aacrjournals.org/cancerres/ar...
A project initiated by the @su2c.bsky.social Breast Cancer Dream Team was published in npj precision oncology utilizing cohort-level and individual networks to predict best response in patients with metastatic triple negative breast cancer www.nature.com/articles/s41...
www.nature.com
July 14, 2025 at 1:34 PM
A project initiated by the @su2c.bsky.social Breast Cancer Dream Team was published in npj precision oncology utilizing cohort-level and individual networks to predict best response in patients with metastatic triple negative breast cancer www.nature.com/articles/s41...
New Request for Applications! The @su2c.bsky.social Lung Cancer Early Detection Challenge is open! For information, please click the link below or search Stand Up To Cancer in Proposal Central under Grant Opportunities. #LungCancer #EarlyDetection #StandUpToCancer standuptocancer.org/science/gran...
Grant and Award Opportunities | Stand Up To Cancer®
Stand Up To Cancer (SU2C) grants and awards fund cancer research projects that address critical problems in patient care and deliver near-term patient benefit through both individual and collaborative...
standuptocancer.org
July 11, 2025 at 3:08 PM
New Request for Applications! The @su2c.bsky.social Lung Cancer Early Detection Challenge is open! For information, please click the link below or search Stand Up To Cancer in Proposal Central under Grant Opportunities. #LungCancer #EarlyDetection #StandUpToCancer standuptocancer.org/science/gran...
The @su2c.bsky.social Multiple Myeloma Dream Team published in @natgenet.nature.com describing their MM precursor genomic map in order to better inform risk assessment and monitoring of MM precursor conditions. www.nature.com/articles/s41...
Genomic landscape of multiple myeloma and its precursor conditions - Nature Genetics
The genomic features of precursor conditions of multiple myeloma provide multiple biological insights into disease origins and evolution, together with opportunities to identify those at highest risk ...
www.nature.com
June 23, 2025 at 1:57 PM
The @su2c.bsky.social Multiple Myeloma Dream Team published in @natgenet.nature.com describing their MM precursor genomic map in order to better inform risk assessment and monitoring of MM precursor conditions. www.nature.com/articles/s41...
Check out the upcoming New York Academy of Sciences Frontiers in Cancer Immunology Symposium. The event features several current and former @SU2C – funded researchers including @bengrbm.bsky.social, Jim Allison, Antoni Ribas, Taha Merghoub, and Padmanee Sharma. #immunology #cancer
June 9, 2025 at 6:52 PM
Check out the upcoming New York Academy of Sciences Frontiers in Cancer Immunology Symposium. The event features several current and former @SU2C – funded researchers including @bengrbm.bsky.social, Jim Allison, Antoni Ribas, Taha Merghoub, and Padmanee Sharma. #immunology #cancer
A new method shows unexpected behavior in molecular crowding during cell state transitions suggests density as a biomarker for precision medicine per a paper in @natbiomedeng.nature.com from @su2c.bsky.social Convergence 3.1416 Research Teams Scott Manalis @mit.edu www.nature.com/articles/s41...
High-throughput single-cell density measurements enable dynamic profiling of immune cell and drug response from patient samples - Nature Biomedical Engineering
A platform for profiling single-cell density reveals insights into the regulation of cell density homeostasis and patient drug responses.
www.nature.com
May 29, 2025 at 5:47 PM
A new method shows unexpected behavior in molecular crowding during cell state transitions suggests density as a biomarker for precision medicine per a paper in @natbiomedeng.nature.com from @su2c.bsky.social Convergence 3.1416 Research Teams Scott Manalis @mit.edu www.nature.com/articles/s41...
cfDNA approaches can identify therapeutic response of #pancreaticcancer patients per a paper from Victor Velculescu of the @su2c.bsky.social-@nkinl.bsky.social and @su2c.bsky.social y.social-@lungusa.bsky.social-@lungevity.bsky.social Dream Teams https://www.science.org/doi/10.1126/sciadv.ads5002
Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer
Noninvasive mutation-based and fragmentation-based cfDNA approaches can identify response to therapy in pancreatic cancer.
www.science.org
May 22, 2025 at 6:25 PM
cfDNA approaches can identify therapeutic response of #pancreaticcancer patients per a paper from Victor Velculescu of the @su2c.bsky.social-@nkinl.bsky.social and @su2c.bsky.social y.social-@lungusa.bsky.social-@lungevity.bsky.social Dream Teams https://www.science.org/doi/10.1126/sciadv.ads5002
Work from the @su2c.bsky.socialConvergence 3.1416 Research Team led by Dan Littman from NYU and a Sharp Award was published in @nature.com describing how dendritic cells are able to regulate T cell responses to food and microbes and contribute to food tolerance www.nature.com/articles/s41...
PRDM16-dependent antigen-presenting cells induce tolerance to gut antigens - Nature
A subset of antigen-presenting cells of myeloid origin that require PRDM16 and RORγt regulates T cell function to enable immune tolerance of food and commensal gut microorganisms.
www.nature.com
May 21, 2025 at 8:58 PM
Work from the @su2c.bsky.socialConvergence 3.1416 Research Team led by Dan Littman from NYU and a Sharp Award was published in @nature.com describing how dendritic cells are able to regulate T cell responses to food and microbes and contribute to food tolerance www.nature.com/articles/s41...
Gerrit Meijer from the @su2cscience.bsky.social-#KWF MEDOCC team presented the Team’s work in developing the multi-target FIT test for colorectal cancer at the @nkinl.bsky.social Early Cancer Detection Conference #StandUpToCancer #NetherlandsCancerInstitute #colorectalcancer
May 15, 2025 at 12:45 PM
Gerrit Meijer from the @su2cscience.bsky.social-#KWF MEDOCC team presented the Team’s work in developing the multi-target FIT test for colorectal cancer at the @nkinl.bsky.social Early Cancer Detection Conference #StandUpToCancer #NetherlandsCancerInstitute #colorectalcancer
80% of patients with early stage dMMR solid tumors treated with dostarlimab avoided surgery, chemotherapy or radiation after treatment per a paper published in @nejm.org by Andrea Cercek @mskcancercenter.bsky.social of the @su2c.bsky.social Colorectal Cancer Dream Team
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Nonoperative Management of Mismatch Repair–Deficient Tumors | NEJM
Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer,
neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion
of patients. Whether this ...
www.nejm.org
May 5, 2025 at 8:39 PM
80% of patients with early stage dMMR solid tumors treated with dostarlimab avoided surgery, chemotherapy or radiation after treatment per a paper published in @nejm.org by Andrea Cercek @mskcancercenter.bsky.social of the @su2c.bsky.social Colorectal Cancer Dream Team
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
The @su2c.bsky.social Catalyst @genentech.bsky.socia Team published in the Journal for ImmunoTherapy of Cancer a low rate of distant metastasis differences in gut microbiome structure in patients enrolled in the NeoACTIVATE trial jitc.bmj.com/content/13/4...
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Background Neoadjuvant treatment has become standard for patients with high-risk operable stage III melanoma, but the optimal regimen is unknown. Targeted therapy approaches yield high pathological re...
jitc.bmj.com
April 21, 2025 at 8:29 PM
The @su2c.bsky.social Catalyst @genentech.bsky.socia Team published in the Journal for ImmunoTherapy of Cancer a low rate of distant metastasis differences in gut microbiome structure in patients enrolled in the NeoACTIVATE trial jitc.bmj.com/content/13/4...
Congratulation to the 2025 class of Fellows of the @theaacr.bsky.social Academy and @su2cscience.bsky.social community members Nina Bhardwaj from Mount Sinai, Stephan Grupp and Robert Vonderheide@penncancer.bsky.social, Ari Melnick @weillcornell.bsky.social, William Sellers @broadinstitute.org!!
April 18, 2025 at 1:09 PM
Congratulation to the 2025 class of Fellows of the @theaacr.bsky.social Academy and @su2cscience.bsky.social community members Nina Bhardwaj from Mount Sinai, Stephan Grupp and Robert Vonderheide@penncancer.bsky.social, Ari Melnick @weillcornell.bsky.social, William Sellers @broadinstitute.org!!
In February, members of the #StandUpToCancer - Van Andel Institute #Epigenetics Dream Team, Ben Youngblood from St. Jude Children's Research Hospital, and Kirsten Grønbaek from Rigshospitalet, presented at the AACR DNA #Methylation, Clonal Hematopoiesis, and #Cancer Special Conference in San Diego.
March 27, 2025 at 1:35 PM
In February, members of the #StandUpToCancer - Van Andel Institute #Epigenetics Dream Team, Ben Youngblood from St. Jude Children's Research Hospital, and Kirsten Grønbaek from Rigshospitalet, presented at the AACR DNA #Methylation, Clonal Hematopoiesis, and #Cancer Special Conference in San Diego.
An new publication in @Nature by SU2C Convergence Team leaders @thevinodlab.bsky.social @bengrbm.bsky.social @mskcancercenter.bsky.social showed an individualized neoantigen mRNA vaccine for #pancreaticcancer led to prolonged survival and effector T cell responses www.nature.com/articles/s41...
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer - Nature
In a phase 1 trial, patients with pancreatic ductal adenocarcinoma who were treated with surgery and bespoke neoantigen mRNA vaccines combined with anti-PD-L1 and chemotherapy exhibited marked lo...
www.nature.com
February 20, 2025 at 7:14 PM
An new publication in @Nature by SU2C Convergence Team leaders @thevinodlab.bsky.social @bengrbm.bsky.social @mskcancercenter.bsky.social showed an individualized neoantigen mRNA vaccine for #pancreaticcancer led to prolonged survival and effector T cell responses www.nature.com/articles/s41...